benign prostatic hyperplasia (BPH)

From Aaushi
Jump to navigation Jump to search

Introduction

A common disorder of men over the age of 50 characterized by enlargement of the prostate which may press against the urethra & obstruct the flow of urine. BPH is the most common cause of such anatomic obstruction in elderly men.

Etiology

Epidemiology

Pathology

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Complications

Differential diagnosis

Management

More general terms

Additional terms

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
    Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 19. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2022.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  3. Aronson WJ. in: UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  4. 4.0 4.1 Prescriber's Letter 9(7):41 2002
  5. 5.0 5.1 5.2 5.3 Journal Watch 24(3):21, 2004 McConnell JD et al, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14681504
  6. 6.0 6.1 6.2 Prescriber's Letter 11(1):3 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200105&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. 7.0 7.1 Bent S et al, Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006, 354:557 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16467543
    Prescriber's Letter 13(3): 2006 Special Report: Natural Medicines in Clinical Management of Benign Prostatic Hyperplasia Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220305&pb=PRL (subscription needed) http://www.prescribersletter.com
    MacDonald R, Tacklind JW, Rutks I, Wilt TJ Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012 Jun;109(12):1756-61. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22551330
  8. 8.0 8.1 Prescriber's Letter 14(2): 2007 Pharmacotherapy of BPH with overactive bladder Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230205&pb=PRL (subscription needed) http://www.prescribersletter.com
  9. Lepor H et al, The efficacy of terazosin, finasteride or both in benign prostatic hypertrophy. N Engl J Med 335:533 PMID: https://www.ncbi.nlm.nih.gov/pubmed/8684407
  10. 10.0 10.1 Roehrborn CG, Siami P, Barkin J, Damio R, Major-Walker K, Morrill B, Montorsi F; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008 Feb;179(2):616-21; discussion 621. Epub 2007 Dec 21. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18082216
  11. 11.0 11.1 11.2 Johnson TM 2nd, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, Roehrborn CG; Medical Therapy of Prostatic Symptoms Research Group. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007 Nov;178(5):2045-50; discussion 2050-1. Epub 2007 Sep 17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17869295
  12. Prescriber's Letter 15(8): 2008 COMMENTARY: Combination Therapy for Benign Prostatic Hyperplasia (BPH) GUIDELINES: Management of Benign Prostatic Hyperplasia (Summary) GUIDELINES: Management of Benign Prostatic Hyperplasia (Canadian Guidelines) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240806&pb=PRL (subscription needed) http://www.prescribersletter.com
  13. 13.0 13.1 MacDiarmid SA et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: Randomized, double-blind, placebo- controlled study. Mayo Clin Proc 2008 Sep; 83:1002. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18775200
  14. 14.0 14.1 Idan A et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: A randomized, placebo-controlled trial. Ann Intern Med 2010 Nov 15; 153:621. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21079217
  15. 15.0 15.1 Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. Curr Opin Urol. 2012 Jan;22(1):34-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22123290
  16. 16.0 16.1 Toren P et al Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ 2013;346:f2109 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23587564
  17. Greco KA, McVary KT. The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19002123
  18. 18.0 18.1 18.2 18.3 Filson CP et al. The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: A meta-analysis. J Urol 2013 Dec; 190:2153 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23727412
    NEJM Journal Watch. Jan 16, 2014 http://www.jwatch.org (subscription required)
  19. Paolone DR. Benign prostatic hyperplasia. Clin Geriatr Med. 2010 May;26(2):223-39 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20497842
  20. 20.0 20.1 Roehrborn CG et al. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol 2014 Apr; 191:1045 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24445278 <Internet> http://dx.doi.org/10.1016/j.juro.2013.10.074#sthash.Z5obxJcP.dpuf
  21. McVary KT, Roehrborn CG, Avins AL et al Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011 May;185(5):1793-803. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21420124
  22. 22.0 22.1 McVary KT et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2014 Jul; 192:150. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24508634 <Internet> http://www.jurology.com/article/S0022-5347%2814%2900249-3/abstract
  23. 23.0 23.1 23.2 Fullhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013;64:228-243 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23375241
  24. 24.0 24.1 Shankar E, Bhaskaran N, MacLennan GT et al Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases. J Urol Res. 2015 Jan 1;2(1). pii: 1018. Epub 2015 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26417612
  25. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003 Aug;170(2 Pt 1):530-47. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12853821
  26. Beckman TJ, Mynderse LA. Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc. 2005 Oct;80(10):1356-62. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16212149
  27. 27.0 27.1 Lee SH, Lee JY. Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int. 2014;2(2):43-9. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25032191 Free PMC Article
  28. 28.0 28.1 Matsukawa Y, Takai S, Funahashi Y et al Effects of Withdrawing alpha1-Blocker from Combination Therapy with alpha1-Blocker and 5alpha-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics. J Urol. 2017 Oct;198(4):905-912. Epub 2017 May 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28499730
  29. Foster HE, Barry MJ, Dahm P, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol. May 15, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29775639 https://www.ncbi.nlm.nih.gov/pubmed/29775639
  30. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012 Jul 20; 367:248 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22808960 https://www.nejm.org/doi/full/10.1056/NEJMcp1106637
  31. 31.0 31.1 31.2 Huang SW, Tsai CY, Tseng CS et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis. BMJ 2019 Nov 14; 367:l5919 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31727627 Free Article
  32. 32.0 32.1 Ayyagari R, Powell T, Staib L et al. Prostatic artery embolization in nonindex benign prostatic hyperplasia patients: Single-center outcomes for urinary retention and gross prostatic hematuria. Urology 2020 Feb; 136:212. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31734349 https://www.goldjournal.net/article/S0090-4295(19)30971-9/fulltext
  33. 33.0 33.1 33.2 Lerner LB, McVary KT, Barry MJ et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I - Initial work-up and medical management. J Urol 2021 Oct; 206:806-817. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34384237 https://www.auajournals.org/doi/10.1097/JU.0000000000002183
    Lerner LB, McVary KT, Barry MJ et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II - Surgical evaluation and treatment. J Urol 2021 Oct; 206:818 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34384236 https://www.auajournals.org/doi/10.1097/JU.0000000000002184
  34. Wolinsky H A 'Cup of Tea' for the Prostate Improves Urine Flow. Medscape. Feb 24, 2922 https://www.medscape.com/viewarticle/969052
    Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Large, Multi-Center, Prospective Registry of Rezum Water Vapor Therapy for Benign Prostatic Hyperplasia. Urology. 2022 Feb 17:S0090-4295(22)00142-X PMID: https://www.ncbi.nlm.nih.gov/pubmed/35182585
  35. 35.0 35.1 Lenfant L et al. Role of antimuscarinics combined with alpha-blockers in the management of urinary storage symptoms in patients with benign prostatic hyperplasia: An updated systematic review and meta-analysis. J Urol 2023 Feb; 209:314. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36395428 https://www.auajournals.org/doi/10.1097/JU.0000000000003077
  36. 36.0 36.1 36.2 NEJM Knowledge+ Nephrology/Urology
  37. Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. 2020;12:1756287220929486. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32547642
  38. Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of overactive bladder (Non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558-563. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31039103
  39. Prostate Enlargement: Benign Prostatic Hyperplasia http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/index.htm
    Medical Tests for Prostate Problems http://kidney.niddk.nih.gov/kudiseases/pubs/prostatetests/index.htm

Patient information

benign prostatic hypertrophy patient information